- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
- Drug
- Lead sponsor
- Oxurion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Boston, Massachusetts • Reno, Nevada + 4 more
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept
- Drug
- Lead sponsor
- Oxurion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 18
- States / cities
- Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Interventions
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Campbell, California • Irvine, California + 6 more